235 related articles for article (PubMed ID: 12944467)
1. Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution.
Cheng WH; von Kobbe C; Opresko PL; Fields KM; Ren J; Kufe D; Bohr VA
Mol Cell Biol; 2003 Sep; 23(18):6385-95. PubMed ID: 12944467
[TBL] [Abstract][Full Text] [Related]
2. Werner protein is a target of DNA-dependent protein kinase in vivo and in vitro, and its catalytic activities are regulated by phosphorylation.
Karmakar P; Piotrowski J; Brosh RM; Sommers JA; Miller SP; Cheng WH; Snowden CM; Ramsden DA; Bohr VA
J Biol Chem; 2002 May; 277(21):18291-302. PubMed ID: 11889123
[TBL] [Abstract][Full Text] [Related]
3. BCR/ABL stimulates WRN to promote survival and genomic instability.
Slupianek A; Poplawski T; Jozwiakowski SK; Cramer K; Pytel D; Stoczynska E; Nowicki MO; Blasiak J; Skorski T
Cancer Res; 2011 Feb; 71(3):842-51. PubMed ID: 21123451
[TBL] [Abstract][Full Text] [Related]
4. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
5. Nuclear DNA helicase II (RNA helicase A) interacts with Werner syndrome helicase and stimulates its exonuclease activity.
Friedemann J; Grosse F; Zhang S
J Biol Chem; 2005 Sep; 280(35):31303-13. PubMed ID: 15995249
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the autoinhibition of c-Abl tyrosine kinase.
Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J
Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251
[TBL] [Abstract][Full Text] [Related]
8. Werner syndrome protein is regulated and phosphorylated by DNA-dependent protein kinase.
Yannone SM; Roy S; Chan DW; Murphy MB; Huang S; Campisi J; Chen DJ
J Biol Chem; 2001 Oct; 276(41):38242-8. PubMed ID: 11477099
[TBL] [Abstract][Full Text] [Related]
9. A myristoyl/phosphotyrosine switch regulates c-Abl.
Hantschel O; Nagar B; Guettler S; Kretzschmar J; Dorey K; Kuriyan J; Superti-Furga G
Cell; 2003 Mar; 112(6):845-57. PubMed ID: 12654250
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase 1 regulates both the exonuclease and helicase activities of the Werner syndrome protein.
von Kobbe C; Harrigan JA; Schreiber V; Stiegler P; Piotrowski J; Dawut L; Bohr VA
Nucleic Acids Res; 2004; 32(13):4003-14. PubMed ID: 15292449
[TBL] [Abstract][Full Text] [Related]
11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
13. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
Schindler T; Bornmann W; Pellicena P; Miller WT; Clarkson B; Kuriyan J
Science; 2000 Sep; 289(5486):1938-42. PubMed ID: 10988075
[TBL] [Abstract][Full Text] [Related]
14. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
15. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
[TBL] [Abstract][Full Text] [Related]
16. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Druker BJ; Tamura S; Buchdunger E; Ohno S; Segal GM; Fanning S; Zimmermann J; Lydon NB
Nat Med; 1996 May; 2(5):561-6. PubMed ID: 8616716
[TBL] [Abstract][Full Text] [Related]
17. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.
Liang X; Hajivandi M; Veach D; Wisniewski D; Clarkson B; Resh MD; Pope RM
Proteomics; 2006 Aug; 6(16):4554-64. PubMed ID: 16858728
[TBL] [Abstract][Full Text] [Related]
18. Werner syndrome protein. I. DNA helicase and dna exonuclease reside on the same polypeptide.
Shen JC; Gray MD; Oshima J; Kamath-Loeb AS; Fry M; Loeb LA
J Biol Chem; 1998 Dec; 273(51):34139-44. PubMed ID: 9852073
[TBL] [Abstract][Full Text] [Related]
19. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
20. Coordinate action of the helicase and 3' to 5' exonuclease of Werner syndrome protein.
Opresko PL; Laine JP; Brosh RM; Seidman MM; Bohr VA
J Biol Chem; 2001 Nov; 276(48):44677-87. PubMed ID: 11572872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
